|
6. Laboratory Retention Periods and Reports
<br />Specimen retention ae Specimens that are confirmed by the laboratory to be positive, adulterated,
<br />substituted, or invalid will be retained by the laboratory in properly secured, long-term, frozen storage
<br />for at least 365 days. Within this 365 day period, the MRO, the employee, the Company, PHMSA or
<br />other state agencies with jurisdiction, may request in writing that the specimens be retained for an
<br />additional period. If the laboratory does not receive the request to retain the specimen within the 365-
<br />day period, the specimen will be discarded.
<br />Record retention .60 All laboratory records pertaining to any test for this Company on its covered
<br />employees will be retained for two years. The employer -specific data that is created by the laboratory
<br />for the laboratory statistical summary will be retained for two years.
<br />Semi-annual reports 51 The laboratory will prepare and send to the Company the aggregate
<br />employer -specific summary on a semi-annual basis. The format for this report is found in Part 40,
<br />Appendix B.
<br />7. Laboratory Quality Control
<br />Inspections. The laboratory shall permit inspections by the Company, the PHMSA Administrator, or
<br />if the Company is subject to the jurisdiction of a state agency, a representative of the state agency.
<br />Additigpgfly,if the Comi2any uses il PZEA, Jbgt,gITE6may uct ri i s ction of the
<br />laboratory on the behalf of the odm argyles Lhatare clients of the /TPA.
<br />Quality control .62 If the Company, or any C/TPA employed by the Company, has 2000 or more
<br />covered employees, the Company, or C/TPA, will submit quality control specimens to any laboratory
<br />where they have more than 100 specimens tested each year. The rate of quality control specimens is
<br />1 % with a cap at 50 per quarter. At any time that the Company, or any C/TPA employed by the
<br />Company, reaches the 2000-employee threshold, quality control specimen will be submitted following
<br />the specifications of Part 40. Quality control specimens, known as `blind" specimens, submitted to the
<br />laboratory, will appear to be real, employee specimens. The MRO will be informed of each test result
<br />and expected outcome.
<br />Reporting discrepancies. The MRO will inform the Company or its C/TPA of any discrepancy in the
<br />expected result of any blind specimen. The MRO and C/TPA will resolve any discrepancies in the
<br />expected outcomes with this testing. If the unexpected outcome is positive, adulterated, or substituted
<br />where the expected outcome was to be negative, the MRO will report this result directly to
<br />DOT/ODAPC, in accordance with Part 40.
<br />8. MRO Review of Drug Test Results
<br />Compliance .-r'3 The Company will have, on staff or contract for the services of, an MRO who is a
<br />licensed physician with knowledge of drug abuse and is qualified under Part 40. The MRO will follow
<br />the requirements of Part 40 in carrying out the functions of the "independent and impartial gatekeeper
<br />of the drug testing process." A full description of DOT MRO requirements can be found in Part 40,
<br />Subpart G ("Medical Review Officers and the Verification Process"), and Subpart H (Split Specimen
<br />Testing).
<br />Dutles 54 All confirmed drug test results for the Company are received by the MRO directly from the
<br />laboratory. The MRO is responsible for the review of both negative and non -negative test results,
<br />review of the CCFs associated with each test, and to conduct quality control reviews of the MRO
<br />staff. The MRO will review and interpret confirmed positive, adulterated, substituted, and invalid test
<br />results. In carrying out this responsibility, the MRO shall examine alternate medical explanations for
<br />any positive, adulterated, substituted, or invalid test result. This action would include conducting a
<br />medical interview with the employee and review of the employee's medical history, or review of any
<br />other relevant biomedical factors, such as the results of a physical examination following an opiate
<br />positive. The MRO shall review medical records made available by the tested employee when the
<br />source of the confirmed result could have been from legally prescribed medication. The MRO shall
<br />J. RANCK ELECTRIC, INC.
<br />PHMSA DRI IG/ALCOHOL PLAN
<br />: NA710NAI_ COMPLIANCE MANAGEMENT SERVICE, INC.'140108)-2D10 24
<br />
|